Cancer Ongoing 2020 North Florida / Jacksonville: Astrid Corrales-Cruz (904) 427-1217

Astellas 2215-CL-0302

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Trial overview

Blood cancer treatment and diagnosis – TBC
Astellas 2215-CL-0302
The purpose of this study is to determine the clinical benefit of ASP2215 therapy in patients with FMS-like tyrosine kinase (FLT3) mutated acute myeloid leukemia (AML) who are refractory to or have relapsed after first-line AML therapy as shown with overall survival (OS) compared to salvage chemotherapy, and to determine the efficacy of ASP2215 therapy as assessed by the rate of complete remission and complete remission with partial hematological recovery (CR/CRh) in these participants.

Dr. Troy H. Guthrie, Jr.


Medical Oncologist

Works at 2 centers.